Jonathan E. Lim, M.D.
About Jonathan E. Lim, M.D.
Jonathan E. Lim, M.D. is a physician and entrepreneur who co-founded Erasca and has led multiple biotechnology companies to develop and launch several therapeutic products in oncology and immunology.
Jonathan E. Lim, M.D.: Chairman, CEO, and Co-founder
Jonathan E. Lim, M.D., is the Chairman, CEO, and Co-founder of Erasca. Bringing his rich experience as a physician-turned-venturepreneur, he has been pivotal in shaping the landscape of biotechnology and healthcare. At City Hill and ARCH Venture, Dr. Lim has contributed to the genesis and growth of groundbreaking biotechnological companies, focusing on creating efficacious therapies and bringing them from concept to market.
Erasca Co-founder
Jonathan E. Lim, M.D., co-founded Erasca in July 2018. Erasca is dedicated to advancing precision oncology, pursuing innovations that aim to alleviate cancer burden through transformative drug development. Under his leadership, Erasca continues to explore new frontiers in precision oncology, striving to develop therapies that target the genetic drivers of cancer and offer new hope to patients worldwide.
Biotechnology Leadership and Achievements
Jonathan E. Lim, M.D., has served as Chairman and/or CEO and founding investor of six biotechnology companies. These companies have collectively achieved the global regulatory approval and launch of seven therapeutic products spanning oncology, immunology, and drug delivery. His leadership roles in these companies underscore his commitment to advancing medical science and bringing critical therapies to the global market.
Pioneering Drug Delivery and Precision Oncology
Jonathan E. Lim, M.D., has pioneered significant advancements in drug delivery and precision oncology. He was instrumental in the design and execution of landmark deals for Halozyme’s ENHANZE drug delivery technology with Roche/Genentech and Baxter. His efforts have set new standards in how therapies are delivered, enhancing their efficacy and patient convenience.
Leadership in Transforming Cancer Treatment
Jonathan E. Lim, M.D., played a key role in leading Ignyta’s pursuit of a global tissue agnostic label, transforming cancer treatment with ROZLYTREK (entrectinib). This effort was aimed at targeting cancer's genetic alterations irrespective of the tissue origin, leading to breakthroughs in how cancer is understood and treated. Dr. Lim continues to contribute to this ongoing evolution at Erasca, inspiring innovations in precision oncology.